Brandon Folkes
Stock Analyst at HC Wainwright & Co.
(2.21)
# 3,250
Out of 5,182 analysts
117
Total ratings
35.54%
Success rate
-0.2%
Average return
Main Sectors:
Stocks Rated by Brandon Folkes
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EPRX Eupraxia Pharmaceuticals | Reiterates: Buy | $11 | $7.11 | +54.71% | 6 | Apr 22, 2026 | |
| ACHV Achieve Life Sciences | Reiterates: Buy | $12 | $4.27 | +181.03% | 4 | Apr 16, 2026 | |
| SINT Sintx Technologies | Initiates: Buy | $10 | $2.15 | +365.12% | 1 | Apr 13, 2026 | |
| RANI Rani Therapeutics Holdings | Reiterates: Buy | $11 | $0.87 | +1,167.28% | 5 | Mar 27, 2026 | |
| DERM Journey Medical | Reiterates: Buy | $13 | $5.26 | +147.15% | 3 | Mar 26, 2026 | |
| COLL Collegium Pharmaceutical | Reiterates: Buy | $60 | $32.81 | +82.87% | 9 | Mar 20, 2026 | |
| PTHS Pelthos Therapeutics | Reiterates: Buy | $60 | $24.97 | +140.29% | 2 | Mar 19, 2026 | |
| SGMT Sagimet Biosciences | Reiterates: Buy | $29 | $8.75 | +231.43% | 3 | Mar 11, 2026 | |
| TRVI Trevi Therapeutics | Reiterates: Buy | $21 | $13.84 | +51.73% | 4 | Mar 9, 2026 | |
| XERS Xeris Biopharma Holdings | Reiterates: Buy | $10 | $6.09 | +64.20% | 5 | Mar 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $11 → $8 | $2.79 | +186.74% | 9 | Feb 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $13 | $4.43 | +193.45% | 5 | Feb 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $9 | $1.37 | +556.93% | 3 | Feb 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $20 | $13.75 | +45.45% | 3 | Feb 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $18 → $13 | $7.57 | +71.73% | 5 | Jan 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $6 | $1.21 | +395.87% | 3 | Jan 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $40 | $14.67 | +172.67% | 4 | Jan 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $8 | $1.85 | +332.43% | 4 | Jan 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8 | $1.21 | +561.16% | 1 | Dec 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $1.45 | +589.66% | 1 | Sep 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $93 → $121 | $78.50 | +54.14% | 6 | Sep 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $18 | $5.53 | +225.50% | 2 | Aug 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $7 | $2.40 | +191.67% | 2 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $26 | $9.90 | +162.63% | 1 | Jul 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $5 | $0.89 | +461.80% | 1 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $200 | $1.56 | +12,720.51% | 1 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $16 | $8.23 | +94.41% | 6 | Sep 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $455 | $6.90 | +6,494.20% | 1 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $59 | $18.70 | +215.51% | 4 | Sep 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $180 | $203.98 | -11.76% | 2 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $300 → $220 | $2.29 | +9,506.99% | 3 | Dec 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $28 → $32 | $34.14 | -6.27% | 3 | Jan 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $22,000 | $1.04 | +2,115,284.62% | 1 | Aug 31, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $405 → $315 | $9.60 | +3,181.25% | 3 | Mar 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $42 → $50 | $9.61 | +420.29% | 1 | Jul 12, 2018 |
Eupraxia Pharmaceuticals
Apr 22, 2026
Reiterates: Buy
Price Target: $11
Current: $7.11
Upside: +54.71%
Achieve Life Sciences
Apr 16, 2026
Reiterates: Buy
Price Target: $12
Current: $4.27
Upside: +181.03%
Sintx Technologies
Apr 13, 2026
Initiates: Buy
Price Target: $10
Current: $2.15
Upside: +365.12%
Rani Therapeutics Holdings
Mar 27, 2026
Reiterates: Buy
Price Target: $11
Current: $0.87
Upside: +1,167.28%
Journey Medical
Mar 26, 2026
Reiterates: Buy
Price Target: $13
Current: $5.26
Upside: +147.15%
Collegium Pharmaceutical
Mar 20, 2026
Reiterates: Buy
Price Target: $60
Current: $32.81
Upside: +82.87%
Pelthos Therapeutics
Mar 19, 2026
Reiterates: Buy
Price Target: $60
Current: $24.97
Upside: +140.29%
Sagimet Biosciences
Mar 11, 2026
Reiterates: Buy
Price Target: $29
Current: $8.75
Upside: +231.43%
Trevi Therapeutics
Mar 9, 2026
Reiterates: Buy
Price Target: $21
Current: $13.84
Upside: +51.73%
Xeris Biopharma Holdings
Mar 2, 2026
Reiterates: Buy
Price Target: $10
Current: $6.09
Upside: +64.20%
Feb 27, 2026
Maintains: Buy
Price Target: $11 → $8
Current: $2.79
Upside: +186.74%
Feb 11, 2026
Reiterates: Buy
Price Target: $13
Current: $4.43
Upside: +193.45%
Feb 10, 2026
Reiterates: Buy
Price Target: $9
Current: $1.37
Upside: +556.93%
Feb 10, 2026
Reiterates: Buy
Price Target: $20
Current: $13.75
Upside: +45.45%
Jan 23, 2026
Maintains: Buy
Price Target: $18 → $13
Current: $7.57
Upside: +71.73%
Jan 9, 2026
Reiterates: Buy
Price Target: $6
Current: $1.21
Upside: +395.87%
Jan 8, 2026
Maintains: Buy
Price Target: $20 → $40
Current: $14.67
Upside: +172.67%
Jan 6, 2026
Reiterates: Buy
Price Target: $8
Current: $1.85
Upside: +332.43%
Dec 3, 2025
Initiates: Buy
Price Target: $8
Current: $1.21
Upside: +561.16%
Sep 22, 2025
Initiates: Buy
Price Target: $10
Current: $1.45
Upside: +589.66%
Sep 17, 2025
Maintains: Buy
Price Target: $93 → $121
Current: $78.50
Upside: +54.14%
Aug 25, 2025
Reiterates: Buy
Price Target: $18
Current: $5.53
Upside: +225.50%
Aug 13, 2025
Reiterates: Buy
Price Target: $7
Current: $2.40
Upside: +191.67%
Jul 2, 2025
Initiates: Buy
Price Target: $26
Current: $9.90
Upside: +162.63%
Nov 14, 2024
Initiates: Buy
Price Target: $5
Current: $0.89
Upside: +461.80%
Nov 14, 2024
Initiates: Buy
Price Target: $200
Current: $1.56
Upside: +12,720.51%
Sep 13, 2024
Reiterates: Buy
Price Target: $16
Current: $8.23
Upside: +94.41%
Jun 13, 2024
Initiates: Buy
Price Target: $455
Current: $6.90
Upside: +6,494.20%
Sep 26, 2023
Reiterates: Overweight
Price Target: $59
Current: $18.70
Upside: +215.51%
Aug 22, 2023
Reiterates: Overweight
Price Target: $180
Current: $203.98
Upside: -11.76%
Dec 5, 2022
Maintains: Overweight
Price Target: $300 → $220
Current: $2.29
Upside: +9,506.99%
Jan 27, 2022
Upgrades: Overweight
Price Target: $28 → $32
Current: $34.14
Upside: -6.27%
Aug 31, 2021
Initiates: Overweight
Price Target: $22,000
Current: $1.04
Upside: +2,115,284.62%
Mar 5, 2020
Reiterates: Overweight
Price Target: $405 → $315
Current: $9.60
Upside: +3,181.25%
Jul 12, 2018
Maintains: Overweight
Price Target: $42 → $50
Current: $9.61
Upside: +420.29%